Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 4 billion in assets and investment in over 270 companies.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology, New Horizon Bio and Berry Oncology. She also oversees Qiming’s investments in Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics and Jacobio.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, member of Committee on Hong Kong Innovation and Technology Development and Re-Industrialization and advisor of Our Hong Kong Foundation. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.